Dynamk Capital

Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

Bionter is a company focused on transforming analytical testing to enhance public health. It develops innovative analytical testing devices that play a vital role in ensuring patient safety. The company's particle testing services are essential for compliance with mandatory sub-visible particle testing in parenteral preparations. These services are utilized in various applications, including stability testing, drug formulation, process development, and in-process control during manufacturing. By offering advanced light obscuration technology combined with smart automation, Bionter aims to provide clients with improved testing solutions that contribute to the overall safety and efficacy of healthcare products.

Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics. By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.

Virica is a developer of viral sensitizer technology that aims to enhance the manufacturing of viral vector therapeutic products. The company has created a product category known as Viral Sensitizers (VSE™), which includes a library of small molecules. These molecules are identified through a throughput screening process and are designed to target viral infections. Virica's customized VSE formulations aim to optimize research processes and improve production methods for viral medicine producers, facilitating the scalable and cost-effective development of effective viral therapies.

Envisagenics, Inc. is a biotechnology company headquartered in Huntington, New York, specializing in the development of RNA therapeutics. Founded in 2013, the company utilizes its proprietary SpliceCore platform to analyze RNA-seq data through advanced artificial intelligence and machine learning algorithms. This cloud-based technology aims to simplify the complexity of biomedical data, enabling researchers to identify splicing errors that contribute to genetic diseases and cancers. By accurately predicting drug targets and biomarkers, Envisagenics helps pharmaceutical companies reduce the time and costs associated with drug development. The platform is designed to accelerate the discovery of innovative therapeutic solutions and has the potential to address over 370 known human diseases caused by splicing errors. Through collaborations with biopharmaceutical partners, Envisagenics seeks to enhance the efficiency of drug-target selection and lead design, ultimately improving the therapeutic landscape for patients.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012 that focuses on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a proprietary bench-top system that allows for the capture, growth, and analysis of primary cells directly from patient blood samples. This technology is designed to enhance the control of cell phenotype and function, thereby optimizing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to empower researchers with advanced tools for cell maintenance and expansion, ultimately facilitating predictive therapy development and improving clinical outcomes.

Vectron Biosolutions AS develops and markets vector technologies to biotechnology and life science industries. The company offers bacterial cloning vectors; expression vectors engineered for recombinant protein production in bacteria; customize vectors for specific applications; and recombinant proteins. It also provides protein production, vector design, and molecular engineering services to help its clients in life science research activities. Vectron Biosolutions AS was founded in 2008 and is based in Trondheim, Norway.

Alpenglow Biosciences, based in Seattle, Washington, specializes in advanced imaging technology for biological research. The company manufactures flatbed scanners designed for tissue analysis, which generate rich 3D molecular datasets. Its flagship product is an open-top light-sheet microscopy system that allows for the 3D scanning of intact biological samples, enhancing the capabilities of pathologists and researchers. Founded in 2018, Alpenglow aims to modernize pathology and improve the understanding of complex biological processes through its innovative imaging solutions.

Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics. By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.

Lucid Scientific, Inc. is a biotechnology company based in Atlanta, Georgia, focused on enhancing drug discovery and biological research through its innovative real-time cellular activity monitors. The company develops a cell analyzer tool that measures oxygen consumption in standard multi-well plates using proprietary high-resolution optical oxygen sensors. This technology enables researchers in academic institutions and pharmaceutical companies to obtain continuous insights into cellular environments directly from incubators, facilitating more effective drug development and biological studies.

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

RoosterBio, Inc. is a biotechnology company specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine sector. Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio provides human bone marrow and adipose-derived MSCs designed for tissue engineers and cell therapists. These products aim to facilitate the creation of technologies, products, and devices that incorporate living cells. The company's offerings are intended to simplify and accelerate research in regenerative medicine by addressing common challenges in stem cell research and commercialization. RoosterBio has formed strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc., further enhancing its capabilities in the field.

RoosterBio, Inc. is a biotechnology company specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine sector. Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio provides human bone marrow and adipose-derived MSCs designed for tissue engineers and cell therapists. These products aim to facilitate the creation of technologies, products, and devices that incorporate living cells. The company's offerings are intended to simplify and accelerate research in regenerative medicine by addressing common challenges in stem cell research and commercialization. RoosterBio has formed strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc., further enhancing its capabilities in the field.

FloDesign Sonics specializes in innovative acoustic technology aimed at revolutionizing separations and filtration processes across various industries. The company utilizes advanced 3D acoustic standing waves to capture, separate, and purify mixtures without relying on physical membranes, chemicals, or centrifugation. This proprietary technology has significant applications in life sciences, particularly in the bioprocess separations sector for the manufacturing of life-saving biopharmaceuticals, as well as in oil and gas, food and beverage, and industrial processing markets. By offering a more efficient and sustainable method of separation and filtration, FloDesign Sonics is positioned to make a notable impact on these industries.

Envisagenics, Inc. is a biotechnology company headquartered in Huntington, New York, specializing in the development of RNA therapeutics. Founded in 2013, the company utilizes its proprietary SpliceCore platform to analyze RNA-seq data through advanced artificial intelligence and machine learning algorithms. This cloud-based technology aims to simplify the complexity of biomedical data, enabling researchers to identify splicing errors that contribute to genetic diseases and cancers. By accurately predicting drug targets and biomarkers, Envisagenics helps pharmaceutical companies reduce the time and costs associated with drug development. The platform is designed to accelerate the discovery of innovative therapeutic solutions and has the potential to address over 370 known human diseases caused by splicing errors. Through collaborations with biopharmaceutical partners, Envisagenics seeks to enhance the efficiency of drug-target selection and lead design, ultimately improving the therapeutic landscape for patients.

FloDesign Sonics specializes in innovative acoustic technology aimed at revolutionizing separations and filtration processes across various industries. The company utilizes advanced 3D acoustic standing waves to capture, separate, and purify mixtures without relying on physical membranes, chemicals, or centrifugation. This proprietary technology has significant applications in life sciences, particularly in the bioprocess separations sector for the manufacturing of life-saving biopharmaceuticals, as well as in oil and gas, food and beverage, and industrial processing markets. By offering a more efficient and sustainable method of separation and filtration, FloDesign Sonics is positioned to make a notable impact on these industries.